Literature DB >> 2046330

Co-deposition of basement membrane components during the induction of murine splenic AA amyloid.

A W Lyon1, S Narindrasorasak, I D Young, T Anastassiades, J R Couchman, K J McCarthy, R Kisilevsky.   

Abstract

Past studies have demonstrated that during murine AA amyloid induction there is co-deposition of the AA amyloid peptide and the basement membrane form of heparan sulfate proteoglycan. The synthesis and accumulation of heparan sulfate proteoglycan does not usually occur in the absence of other basement membrane components, such as type IV collagen, laminin, and fibronectin. Using immunohistochemical techniques, the present experiments have demonstrated that in addition to the heparan sulfate proteoglycan, there are other basement membrane components present in splenic AA amyloid deposits and these are present as soon as AA amyloid deposits are detectable. The results indicate that within the time constraints imposed by the experiments, the basement membrane components, fibronectin, laminin, type IV collagen, and heparan sulfate proteoglycan are co-deposited 36 to 48 hours after the AgNO3 and amyloid enhancing factor induction of amyloid, the period when amyloid is first detected. These observations raise the possibility that an abnormality in basement membrane metabolism is a very early event, and potentially plays an integral part in the process of AA amyloidogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2046330

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  17 in total

1.  Somatic mutations of the L12a gene in V-kappa(1) light chain deposition disease: potential effects on aberrant protein conformation and deposition.

Authors:  R Vidal; F Goñi; F Stevens; P Aucouturier; A Kumar; B Frangione; J Ghiso; G Gallo
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 2.  Sulfated glycosaminoglycans in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji; Kenji Uchimura
Journal:  Glycoconj J       Date:  2017-04-11       Impact factor: 2.916

Review 3.  Anti-amyloid drugs: potential in the treatment of diseases associated with aging.

Authors:  R Kisilevsky
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 4.  Proteoglycans and other basement membrane proteins in amyloidoses.

Authors:  R Kisilevsky
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

Review 5.  Inflammation-associated amyloidogenesis. Lessons for Alzheimer's amyloidogenesis.

Authors:  R Kisilevsky
Journal:  Mol Neurobiol       Date:  1994-02       Impact factor: 5.590

6.  Increased matrix metalloproteinases as possible cause of osseoarticular tissue destruction in long-term haemodialysis and beta 2-microglobulin amyloidosis.

Authors:  K Ohashi; R Kawai; M Hara; Y Okada; S Tachibana; Y Ogura
Journal:  Virchows Arch       Date:  1996-04       Impact factor: 4.064

7.  On the association between amyloid fibrils and glycosaminoglycans; possible interactive role of Ca2+ and amyloid P-component.

Authors:  T Stenstad; J H Magnus; K Syse; G Husby
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

8.  Proteoglycans in haemodialysis-related amyloidosis.

Authors:  K Ohashi; M Hara; M Yanagishita; R Kawai; S Tachibana; Y Ogura
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid A.

Authors:  J Javier Aguilera; Fuming Zhang; Julie M Beaudet; Robert J Linhardt; Wilfredo Colón
Journal:  Biochimie       Date:  2014-05-28       Impact factor: 4.079

10.  Investigation of the Presence of Apotipoprotein E, G lycosaminoglycans, Basement Membrane Proteins, and Protease inhibitors in Senile interstitial Amyloid of the Pituitary.

Authors:  Christoph Rocken; Diana Paris; Karen Steusloff; Wolfgang Saeger
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.